piracetam has been researched along with oxidopamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antipov, TA; Gudasheva, TA; Kolisnikova, KN; Nazarova, GA; Seredenin, SB; Voronina, TA | 1 |
| Antipova, TA; Gudasheva, TA; Koliasnikova, KN; Seredenin, SB | 1 |
2 other study(ies) available for piracetam and oxidopamine
| Article | Year |
|---|---|
[Similarity of cycloprolylglycine to piracetam in antihypoxic and neuroprotective effects].
Topics: Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Hypercapnia; Hypoxia; Mice; Mice, Inbred BALB C; Neuroprotective Agents; Oxidopamine; Peptides, Cyclic; Piracetam; Sympatholytics | 2012 |
Neuropeptide cycloprolylglycine increases the levels of brain-derived neurotrophic factor in neuronal cells.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Line; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glutamic Acid; Hippocampus; Humans; Mice; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Peptides, Cyclic; Piracetam | 2016 |